(Q54110885)

24 May 2018

title

Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. (English)

1 reference

24 May 2018

0 references

1 reference

1 reference

24 May 2018

author name string

Baert FJ

1 reference

24 May 2018

D'Haens GR

1 reference

24 May 2018

Hiele MI

1 reference

24 May 2018

Schaible TF

1 reference

24 May 2018

Shealy D

1 reference

24 May 2018

Geboes K

1 reference

24 May 2018

Rutgeerts PJ

1 reference

24 May 2018

language of work or name

English

0 references

publication date

1 January 1999

1 reference

24 May 2018

published in

Gastroenterology

1 reference

24 May 2018

volume

116

1 reference

24 May 2018

issue

1 reference

24 May 2018

page(s)

22-28

1 reference

24 May 2018

Tumour necrosis factor-alpha (TNF-alpha): the good, the bad and potentially very effective

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970224-6

Tumor necrosis factor (TNF-alpha) and lymphotoxin (TNF-beta)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970224-6

Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970224-6

Tumour necrosis factor alpha in stool as a marker of intestinal inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970224-6

Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970224-6

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970224-6

The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970224-6

Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970224-6

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970224-6

Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970224-6

Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970224-6

Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970224-6

Impaired mucosal immune responses in interleukin 4-targeted mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970224-6

Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970224-6

10.1016/S0016-5085(99)70224-6

7 January 2021

Identifiers

DOI

1 reference

24 May 2018

1 reference

24 May 2018